Coronavirus (COVID-19) News
Filter News
Found 2,554 articles
-
US Department of Defense Uniformed Services University Clinical Evaluation of Travelan™ Achieves 150 Recruitment Milestone
1/18/2023
Immuron Limited is pleased to provide shareholders and the market with a progress update on the US Department of Defense Uniformed Services University Clinical Evaluation of Travelan.
-
Ascletis Announces Dosing of 4 Healthy Subjects of the First Cohort in Multiple-Dose Escalation Phase I Clinical Trial of Oral 3CLpro Inhibitor ASC11 for COVID-19
1/16/2023
Ascletis Pharma Inc. announces dosing of 4 healthy subjects of the first cohort in multiple-dose escalation Phase I clinical trial of oral 3-chymotrypsin like protease inhibitor ASC11 in combination with 100 mg ritonavir tablets for COVID-19.
-
Clover Provides Updates on COVID-19 Vaccine Commercial Launch and Strategic Priorities in 2023
1/16/2023
Clover Biopharmaceuticals, Ltd., a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, provided updates on the commercialization of SCB-2019 in China and strategic priorities in 2023.
-
Meet Gilead’s COVID-19 Virus Variants Hunters
1/12/2023
Every time a serious new COVID-19 virus variant emerges, Gilead virologists Charlotte Hedskog and John Bilello, alongside their teams, mobilize as so-called "variant hunters."
-
Revive Therapeutics Announces Publication Showing Bucillamine’s Potential Impact on COVID-19 Omicron Variants
1/9/2023
Revive Therapeutics Ltd. announces an independent published study, titled “Omicron Spike Protein Is Vulnerable to Reduction” from the University of Toronto, which evaluated the potential disruption of the SARS-CoV-2 virus spike protein by various FDA-approved mild anti-oxidants has shown that Bucillamine had the most potent effect on COVID-19 Omicron variants when compared to these anti-oxidants being explored as a potential treatment for COVID-19.
-
MedinCell announces positive results for the SAIVE clinical study in prevention of Covid-19 infection in a contact-based population
1/5/2023
The study conducted in 399 participants met its primary efficacy endpoint with a reduction of 72% of COVID-19 infection in the group treated with daily oral administration of ivermectin compared to the placebo group.
-
Lucira Health Submits EUA for Over-The-Counter (OTC) Use of its COVID-19 & Flu Test
1/3/2023
Lucira Health, Inc., a medical technology company, announced that it submitted an Emergency Use Authorization application to the FDA for OTC use of its simple, at-home molecular COVID-19 & Flu test.
-
Spear Bio expands NAB-Sure™ Assays to Support Study of SARS-CoV-2 Variants
1/3/2023
Spear Bio is expanding its NAB-Sure™ Neutralizing Antibody Test Kit product line with current SARS-CoV-2 variants.
-
CGTN: China monitors coronavirus mutations to adjust COVID-19 response
1/1/2023
With China loosening its COVID-19 restrictions, some experts have expressed concern that China's relaxation of COVID-19 limitations will enhance the likelihood of the virus mutating.
-
Government of Canada announces a temporary negative COVID-19 test requirement for travellers arriving from the People's Republic of China, Hong Kong or Macao
12/31/2022
As the COVID-19 pandemic has continued to evolve, the Government of Canada has taken a prudent and measured approach to adjusting border measures to protect the health and safety of Canadians.
-
Novavax Announces Initiation of Phase 2 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates
12/30/2022
Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, announced the initiation of a Phase 2 trial for its COVID-19-Influenza Combination and influenza stand-alone vaccine candidates.
-
Valneva Reports Further Heterologous Booster Data for its inactivated COVID-19 vaccine
12/30/2022
ValnevaSE, a specialty vaccine company, reported further heterologous booster data from an exploratory, small clinical study for its inactivated COVID-19 vaccine, VLA2001.
-
Clene Nanomedicine Reports Topline Results of Phase 2 COVID-19 Study of CNM-ZnAg
12/27/2022
Clene Inc. and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company announced topline study results from its Phase 2 investigational trial with CNM-ZnAg, an ionic solution of zinc and silver, for the treatment of non-hospitalized acutely symptomatic participants infected with COVID-19.
-
Superior Neutralizing Antibody Titer Levels Against Omicron BF.7 And BA.2.75 Of The Company's Two-Component Recombinant COVID-19 Vaccine ReCOV As Compared To International Mainstream mRNA Vaccine
12/26/2022
Jiangsu Recbio Technology Co., Ltd. is pleased to announce that positive results were achieved for its sequential booster vaccination Phase II study of the recombinant two-component COVID-19 vaccine ReCOV in the Philippines.
-
Revive Therapeutics Announces Submission of Type C Meeting Request to FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
12/22/2022
Revive Therapeutics Ltd. announced that it has submitted the Type C meeting request package to the U.S. Food & Drug Administration to obtain agreement on the revised protocol endpoints for the Company’s Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19.
-
Ocugen gets the go-ahead from the FDA to trial its late-stage regenerative cell therapy.
-
More exercise linked to less-severe COVID-19 outcomes
12/15/2022
Kaiser Permanente members who were more physically active prior to being diagnosed with COVID-19 had a lower risk of severe outcomes, according to research published Dec. 15, 2022, in the American Journal of Preventive Medicine.
-
Superior Results Of The Comparative Study Of The Company's Recombinant Two-Component COVID-19 Vaccine ReCOV As Compared To International Mainstream mRNA Vaccine
12/14/2022
Jiangsu Recbio Technology Co., Ltd. is pleased to announce that positive results were achieved for its sequential booster vaccination Phase II study of the recombinant twocomponent COVID-19 vaccine ReCOV in the Philippines.
-
Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by China NMPA
12/7/2022
Ascletis Pharma Inc. announces that China National Medical Products Administration has approved the Investigational New Drug application for ASC11, an oral inhibitor drug candidate targeting 3-chymotrypsin like protease for COVID-19.
-
Kinarus Therapeutics’ KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and BA.5
12/6/2022
Kinarus Therapeutics Holding AG, a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, announced new preclinical data showing KIN001’s strong antiviral efficacy against the SARS-CoV-2 Omicron subvariants BA.2 and BA.5.